Sara Ariotti1, Giuseppe Gargiulo1,2, Marco Valgimigli3. 1. Department of Cardiology, Bern University Hospital, University of Bern, CH-3010, Bern, Switzerland. 2. Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy. 3. Department of Cardiology, Bern University Hospital, University of Bern, CH-3010, Bern, Switzerland. marco.valgimigli@insel.ch.
Abstract
PURPOSE OF REVIEW: This review aims to summarize and discuss safety and effectiveness of the long-term use of ticagrelor in patients with coronary artery disease (CAD). RECENT FINDINGS:Ticagrelor is an orally administered, direct, and reversible inhibitor of the P2Y12-platelet receptor. Long-term use of ticagrelor in patients with previous myocardial infarction (MI) has been investigated in the PEGASUS-TIMI-54 trial. Overall, 21,162 patients with a spontaneous MI 1 to 3 years before randomization were randomly assigned to ticagrelor 90 mg bid, ticagrelor 60 mg bid, or placebo. Compared with placebo, both doses of ticagrelor showed that they were capable of significantly reducing the primary efficacy endpoint, although with a significant increase in TIMI major bleeding. Intracranial hemorrhage or fatal bleeding did not differ across groups. These findings establish clear benefit of DAPT extension with ticagrelor beyond 1 year of treatment, which comes with a tradeoff of clinically meaningful bleeding. Altogether, current evidence suggests that the duration of DAPT remains a patient-by-patient decision based on thrombotic and bleeding risk profiles.
RCT Entities:
PURPOSE OF REVIEW: This review aims to summarize and discuss safety and effectiveness of the long-term use of ticagrelor in patients with coronary artery disease (CAD). RECENT FINDINGS:Ticagrelor is an orally administered, direct, and reversible inhibitor of the P2Y12-platelet receptor. Long-term use of ticagrelor in patients with previous myocardial infarction (MI) has been investigated in the PEGASUS-TIMI-54 trial. Overall, 21,162 patients with a spontaneous MI 1 to 3 years before randomization were randomly assigned to ticagrelor 90 mg bid, ticagrelor 60 mg bid, or placebo. Compared with placebo, both doses of ticagrelor showed that they were capable of significantly reducing the primary efficacy endpoint, although with a significant increase in TIMI major bleeding. Intracranial hemorrhage or fatal bleeding did not differ across groups. These findings establish clear benefit of DAPT extension with ticagrelor beyond 1 year of treatment, which comes with a tradeoff of clinically meaningful bleeding. Altogether, current evidence suggests that the duration of DAPT remains a patient-by-patient decision based on thrombotic and bleeding risk profiles.
Authors: Giovanni Esposito; Gabriele Giacomo Schiattarella; Cinzia Perrino; Fabio Cattaneo; Gianluigi Pironti; Anna Franzone; Giuseppe Gargiulo; Fabio Magliulo; Federica Serino; Giuseppe Carotenuto; Anna Sannino; Federica Ilardi; Fernando Scudiero; Linda Brevetti; Marco Oliveti; Giuseppe Giugliano; Carmine Del Giudice; Michele Ciccarelli; Giovanni Renzone; Andrea Scaloni; Nicola Zambrano; Bruno Trimarco Journal: Cardiovasc Res Date: 2015-06-22 Impact factor: 10.787
Authors: Robert F Storey; Dominick J Angiolillo; Marc P Bonaca; Mark R Thomas; Heather M Judge; Fabiana Rollini; Francesco Franchi; Arif J Ahsan; Deepak L Bhatt; Julia F Kuder; Philippe Gabriel Steg; Marc Cohen; Rangasamy Muthusamy; Eugene Braunwald; Marc S Sabatine Journal: J Am Coll Cardiol Date: 2016-03-15 Impact factor: 24.094
Authors: Sammy Elmariah; Laura Mauri; Gheorghe Doros; Benjamin Z Galper; Kelly E O'Neill; Philippe Gabriel Steg; Dean J Kereiakes; Robert W Yeh Journal: Lancet Date: 2014-11-16 Impact factor: 79.321
Authors: Stefanie Schulz-Schüpke; Robert A Byrne; Jurrien M Ten Berg; Franz-Josef Neumann; Yaling Han; Tom Adriaenssens; Ralph Tölg; Melchior Seyfarth; Michael Maeng; Bernhard Zrenner; Claudius Jacobshagen; Harald Mudra; Eberhard von Hodenberg; Jochen Wöhrle; Dominick J Angiolillo; Barbara von Merzljak; Nonglag Rifatov; Sebastian Kufner; Tanja Morath; Antonia Feuchtenberger; Tareq Ibrahim; Paul W A Janssen; Christian Valina; Yi Li; Walter Desmet; Mohamed Abdel-Wahab; Klaus Tiroch; Christian Hengstenberg; Isabell Bernlochner; Marcus Fischer; Heribert Schunkert; Karl-Ludwig Laugwitz; Albert Schömig; Julinda Mehilli; Adnan Kastrati Journal: Eur Heart J Date: 2015-01-23 Impact factor: 29.983
Authors: M B Leon; D S Baim; J J Popma; P C Gordon; D E Cutlip; K K Ho; A Giambartolomei; D J Diver; D M Lasorda; D O Williams; S J Pocock; R E Kuntz Journal: N Engl J Med Date: 1998-12-03 Impact factor: 91.245
Authors: Stefan James; Dominick J Angiolillo; Jan H Cornel; David Erlinge; Steen Husted; Frederic Kontny; Juan Maya; Josë C Nicolau; Jindrich Spinar; Robert F Storey; Susanna R Stevens; Lars Wallentin Journal: Eur Heart J Date: 2010-08-29 Impact factor: 29.983